Head to Head Analysis: XTL Biopharmaceuticals (XTLB) vs. The Competition

XTL Biopharmaceuticals (NASDAQ:XTLB) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare XTL Biopharmaceuticals to related companies based on the strength of its risk, profitability, valuation, analyst recommendations, dividends, institutional ownership and earnings.

Insider and Institutional Ownership

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares XTL Biopharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
XTL Biopharmaceuticals Competitors	-12,285.98%	-196.04%	-30.61%

Earnings and Valuation

This table compares XTL Biopharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	-$6.97 million	-2.66
XTL Biopharmaceuticals Competitors	$717.36 million	$12.10 million	-14.88

XTL Biopharmaceuticals’ competitors have higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for XTL Biopharmaceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
XTL Biopharmaceuticals Competitors	9858	15137	45528	1590	2.54

As a group, “Biotechnology” companies have a potential upside of 99.39%. Given XTL Biopharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts clearly believe XTL Biopharmaceuticals has less favorable growth aspects than its competitors.

Volatility & Risk

XTL Biopharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals’ competitors have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Summary

XTL Biopharmaceuticals competitors beat XTL Biopharmaceuticals on 7 of the 12 factors compared.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. is an Israeli clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company’s work is centered on treatments intended to regulate abnormal immune-system activity rather than broadly suppressing immune function. XTL’s principal development program has been hCDR1, also known as rigerimod, a synthetic peptide designed to modulate immune responses associated with systemic lupus erythematosus, or lupus. The candidate has been evaluated in clinical development for autoimmune indications, although its regulatory and commercial status may change as the company advances or revises its pipeline.